CD40LG and COVID-19: After confirming that cohort characteristics were comparable, we analyzed the IgM N-glycosylation profiles from day 4 and 7 hospitalized COVID-19 IMPACC patients across mild, moderate, and severe cohorts (Fig. 1C).